RYR2 and catecholaminergic polymorphic ventricular tachycardia 1: Such a pathway-directed approach is particularly valuable in the context of RYR2-related CPVT1, where traditional gene replacement therapy remains technically unfeasible due to the exceptional size of the RYR2 coding sequence, which spans nearly 15,000 nucleotides and exceeds the packaging capacity of current viral vectors.